Gerd Auffarth - 29 Mar 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Director
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Issuer symbol: OTLK
Transactions as of: 29 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 31 Mar 2023, 17:47:57 UTC
Previous filing: 07 Oct 2022
Next filing: 05 Oct 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLK	Stock Option (Right to Buy)	Award	$0	+41,065		$0.000000	41,065	29 Mar 2023	Common Stock	41,065	$1.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Content

The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.